Viewing nowQlorica Capsule 150mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Dasan Pharmaceutical Co., Ltd.

MFDS item code 201801696 · Approved 2018.04.20 · Insurance code 678600880
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in epilepsy patients. Furthermore, it can assist in the treatment of fibromyalgia. In summary, this medication is used for the management of neuropathic pain, as adjunctive therapy for partial seizures in epilepsy, and for alleviating the symptoms of fibromyalgia.
This medication is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys in unchanged form. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the method of administration. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so if you experience mood changes or unusual behaviors while taking it, you should consult your doctor immediately. Individuals with allergies to any ingredients in this medication or with genetic issues such as lactose intolerance should not take it. Diabetic patients should be cautious as weight gain may require dosage adjustments for blood sugar control medications. In case of severe allergic reactions such as angioedema, discontinue the medication immediately and inform your healthcare provider. Elderly patients are at risk of falls due to dizziness or drowsiness, so they should exercise extra caution during the initial stages of treatment. This medication may cause blurred vision or changes in eyesight, and if symptoms persist, you should consult your doctor. Stopping this medication suddenly may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so you should taper off the dosage gradually as directed by your doctor. Patients with a history of substance abuse should take this medication with caution due to the risk of misuse or dependence. Patients with diminished kidney function may require dosage adjustments. Patients with heart conditions should exercise caution when taking this medication. Taking this medication in combination with opioid analgesics may increase the risk of central nervous system depression, so you should consult your healthcare provider. Patients with respiratory diseases, the elderly, or those with kidney disease may have a higher risk of severe respiratory suppression and may need dosage adjustments. In the early stages of pregnancy, there is a risk of congenital malformations, so it is best not to take this medication during pregnancy, and fertile women should use effective contraception. If you are breastfeeding, this medication may be passed into breast milk, so you should discuss with your healthcare provider whether to discontinue breastfeeding or the medication. This medication may cause dizziness and drowsiness, so engaging in activities such as driving or operating machinery should only occur after confirming you are safe to do so after taking the medication. Severe skin reactions may rarely occur, so if there are any unusual skin symptoms, you should stop taking the medication immediately and contact your doctor. In cases of overdose, symptoms such as confusion, drowsiness, and depression may arise, and treatment such as dialysis may be necessary if required. This medication should be stored out of reach of children, and it is safer not to transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to maintain storage temperatures between 15 and 30 degrees Celsius. This helps maintain the medication's efficacy and safety for an extended period.
A hard capsule with white powder inside, with a white upper and lower part.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Dasan Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.